首页> 外文期刊>Cell death discovery. >Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGFβ and focal adhesion kinase (FAK) signaling
【24h】

Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGFβ and focal adhesion kinase (FAK) signaling

机译:乳腺癌中的长非编码RNA(LNCRNA)转录景观鉴定LINC01614作为由TGFβ和局灶性粘附激酶(FAK)信号传导调节的不利预后生物标志物

获取原文
       

摘要

Long non-coding RNAs (lncRNAs) represent a class of epigenetic regulators implicated in a number of physiological and pathological conditions. Herein, we characterized the lncRNA expression portrait from 837 patients with invasive breast cancer and 105 normals from the cancer genome atlas (TCGA), which revealed eighteen upregulated and forty-six downregulated lncRNAs. Clustering analysis revealed distinct lncRNA profile for the triple negative breast cancer (TNBC) and normal breast tissue, while less separation was observed among the HER2sup+/supHRsup+/sup, HER2sup+/supHRsup-/sup, HER2sup-/supHRsup+/sup molecular subtypes. LINC01614, and LINC01235 correlated with worse disease-free survival (DFS), while the expression of lnc-LRR1-1, lnc-ODF3B-2, AC015712.5, lnc-LAMB3-1, lnc-SPP2-3, and lnc-MAP9-2 correlated with better DFS. The expression of LINC01235 correlated with worse overall survival (OS), while the expression of MIR205HG, lnc-MAP2K6-5, FGF14-AS2, lnc-SPP2-3 correlated with better OS. Highest expression of LINC01614 was observed in progesterone receptor (PR)sup+/sup, Estrogen receptor (PR)sup+/sup, and HER2sup+/sup tumors, while lowest expression was in TNBC. Concordantly, LINC01614 was highly expressed in the luminalB/HER2sup+/sup subtype from the SRP062132 dataset. Elevated expression of LINC01614 was subsequently validated in primary breast cancer tissue and breast cancer cell lines. Bioinformatics and pathway analyses on LINC01614suphigh/sup vs. LINC01614suplow/sup BC tissue revealed TGFβ1 and ECM as the most activated networks in LINC01614suphigh/sup tumors. Concordantly, strong correlation between the expression of LINC01614 and COL10A1 (Rsup2/sup?=?0.6929), SPOCK1 (Rsup2/sup?=?0.5156), ZEB1 (Rsup2/sup?=?0.3372), TGFBI (Rsup2/sup?=?0.2978), TGFB1 (Rsup2/sup?=?0.1985), ACTA2 (Rsup2/sup?=?0.1833), and TAGLN (Rsup2/sup?=?0.1909) was observed. Mechanistically, exogenous TGFB1 induced LINC01614 expression in the BT474 triple positive BC model, while small-molecule inhibition of transforming growth factor β (TGFβ, SB-431542) or focal adhesion kinase (FAK, PF-573228) abrogated LINC01614 expression. Our data revealed the lncRNA transcription landscape in breast cancer and its molecular subtypes. Our data provide novel insight implicating LINC01614 as unfavorable prognostic marker in BC, its association with the HRsup+/sup/HER2sup+/sup BC molecular subtype and its regulation by TGFβ and FAK signaling.
机译:长期非编码RNA(LNCRNA)代表一类涉及在许多生理和病理条件下的表观遗传调节剂。在此,我们将来自837例侵袭性乳腺癌患者的LNCRNA表达肖像和来自癌症基因组(TCGA)的105级,其揭示了十八次上调和四十六个下调的LNCRNA。聚类分析显示了三重阴性乳腺癌(TNBC)和正常乳腺组织的不同LNCRNA谱,而HER2 + HR + ,HER2 中观察到较少的分离+ / sup> hr - ,her2 - hr + 分子亚型。 LINC01614和LINC01235与无病的存活(DFS)相关,而LNC-LRR1-1,LNC-ODF3B-2,AC015712.5,LNC-LAMB3-1,LNC-SPP2-3和LNC- MAP9-2与更好的DFS相关联。 LINC01235的表达与差的整体存活率(OS)相关,而MiR205Hg,LNC-MAP2K6-5,FGF14-AS2,LNC-SPP2-3的表达与更好的OS相关。在孕酮受体(PR) + ,雌激素受体(Pr) + 中,观察到最高表达LINC01614,雌激素受体(PR) + 肿瘤,而最低表达在TNBC。一定,LINC01614在SRP062132数据集中的Luminalb / Her2 + 亚型中高度表达。随后在原发性乳腺癌组织和乳腺癌细胞系中验证了LINC01614的升高。 LINC01614 高与Linc01614 低 bc组织揭示了TGFβ1和ECM作为LINC01614 高肿瘤中最活化网络的肿瘤的生物信息学和途径分析。一定,LINC01614和COL10A1的表达与COL10A1(R 2 α=Δ0.6929),SPOCK1(R 2 α=?0.5156),Zeb1(R 2 ?=α= 0.3372),TGFBI(R 2 ?=Δ0978),TGFB1(R 2 ?=?0.1985),ACTA2(R 2 ?=α= 0.1833),并观察到TAGLN(R 2 ?=Δ01909)。机械地,外源性TGFB1诱导李敏01614在BT474三阳性BC模型中的表达,而小分子抑制转化生长因子β(TGFβ,SB-431542)或局灶性粘附激酶(FAK,PF-573228)废弃的LINC01614表达。我们的数据揭示了乳腺癌及其分子亚型中的LNCRNA转录景观。我们的数据在BC中提供了新的Intughting LINC01614作为BC中不利的预后标志物,其与HR + / sup> / her2 + bc分子亚型及其通过Tgfβ和fak信号传导的调节。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号